Moleculin Biotech
Pharmaceuticals, 5300 Memorial Dr, Houston, Texas, 77007, United States, 1-10 Employees
Who is MOLECULIN BIOTECH
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viru...
Read More
-
Headquarters: 5300 Memorial Dr, Houston, Texas, 77007, United States
-
Date Founded: 2006
-
Employees: 1-10
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 452319 |
Show More
Does something look wrong? Fix it. | View contact records from MOLECULIN BIOTECH
Moleculin Biotech Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Moleculin Biotech
Answer: Moleculin Biotech's headquarters are located at 5300 Memorial Dr, Houston, Texas, 77007, United States
Answer: Moleculin Biotech's official website is https://moleculin.com
Answer: Moleculin Biotech's revenue is $10 Million to $25 Million
Answer: Moleculin Biotech's SIC: 2834
Answer: Moleculin Biotech's NAICS: 452319
Answer: Moleculin Biotech has 1-10 employees
Answer: Moleculin Biotech is in Pharmaceuticals
Answer: Moleculin Biotech contact info: Phone number: Website: https://moleculin.com
Answer: Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Companys lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of soft tissue sarcoma (STS) lung metastases and relapsed or refractory acute myeloid leukemia (AML). Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers. Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month